ID

22331

Descripción

A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, This form is to be performed in Treatment Phase. Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Link

https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Palabras clave

Versiones (1)
  1. 30/5/17 30/5/17 -
Subido en

30 de mayo de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

Inglés

Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

1 formularios  
Concomitant Medication
Descripción

Concomitant Medication

Alias
UMLS CUI-1
C2347852
Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
Descripción

Concomitant agent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2347852
Concomitant Medication Changes
Descripción

Concomitant Medication Changes

Alias
UMLS CUI-1
C2347852
Drug name (Trade Name preferred)
Descripción

Drug name

Tipo de datos

text

Alias
UMLS CUI [1]
C0013227
SINGLE Dose/ Unit (e.g. 500mg)
Descripción

Single dose/Unit

Tipo de datos

float

Alias
UMLS CUI [1,1]
C2826257
UMLS CUI [1,2]
C1960417
Frequency of this Dose (e.g. BID PRN)
Descripción

Frequency

Tipo de datos

text

Alias
UMLS CUI [1]
C3476109
Route
Descripción

Concomitant Medication Route of Administration

Tipo de datos

text

Alias
UMLS CUI [1]
C2826730
Indication
Descripción

Indication

Tipo de datos

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C3146298
Start Date/Time
Descripción

Start Date Time

Tipo de datos

datetime

Alias
UMLS CUI [1]
C2827019
End Date/Time
Descripción

Stop Date

Tipo de datos

datetime

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0806020
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1522314
Continuing at end of Study?
Descripción

Continuing at end of study

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1553904
Volver a la parte superior de la página

Similar models

Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Concomitant Medication
C2347852 (UMLS CUI-1)
Concomitant agent
Item
Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
boolean
C2347852 (UMLS CUI [1])
Item Group
Concomitant Medication Changes
C2347852 (UMLS CUI-1)
Drug name
Item
Drug name (Trade Name preferred)
text
C0013227 (UMLS CUI [1])
Single dose/Unit
Item
SINGLE Dose/ Unit (e.g. 500mg)
float
C2826257 (UMLS CUI [1,1])
C1960417 (UMLS CUI [1,2])
Frequency
Item
Frequency of this Dose (e.g. BID PRN)
text
C3476109 (UMLS CUI [1])
Concomitant Medication Route of Administration
Item
Route
text
C2826730 (UMLS CUI [1])
Indication
Item
Indication
text
C2347852 (UMLS CUI [1,1])
C3146298 (UMLS CUI [1,2])
Start Date Time
Item
Start Date/Time
datetime
C2827019 (UMLS CUI [1])
Stop Date
Item
End Date/Time
datetime
C0013227 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C1522314 (UMLS CUI [2,2])
Continuing at end of study
Item
Continuing at end of Study?
boolean
C1553904 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial